文献速递痛风与晶体性关节病

阿那白滞素治疗急性痛风发作:随机双盲安慰剂对照阳性药非劣效试验

Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-02

这项随机双盲阳性对照非劣效试验纳入晶体证实的急性痛风发作患者,比较阿那白滞素与常规治疗(秋水仙碱、萘普生或泼尼松任选)。主要终点第2-4天平均疼痛评分较基线变化,阿那白滞素在PP和ITT人群均达非劣效,两组不良事件无意外或罕见严重事件,症状改善相似。

要点

  • 阿那白滞素在PP人群疼痛变化差异-0.13(95%CI -0.44,0.18),未超过非劣效界值0.4。
  • ITT人群差异-0.18(95%CI -0.44,0.08),同样支持非劣效。
  • 两组均未观察到意外或罕见的(严重)不良事件,症状改善相似。

核心结论

  • 阿那白滞素治疗急性痛风发作的疗效不劣于常规治疗,可作为有效替代选择。

研究设计与样本

  • 随机、双盲、安慰剂对照、阳性药对照、非劣效试验,纳入晶体证实的急性痛风发作患者。
  • 患者按1:1随机接受阿那白滞素或常规治疗(自由选择秋水仙碱、萘普生或泼尼松)。

主要发现

  • 主要终点第2-4天平均疼痛评分较基线变化,阿那白滞素在PP人群差异-0.13(95%CI -0.44,0.18),ITT人群差异-0.18(95%CI -0.44,0.08)。
  • 两组均未观察到意外或罕见的(严重)不良事件。
  • 两组患者痛风症状均报告相似且显著的改善。

关键数值与推荐

  • 非劣效界值为0.4(有利于常规治疗),若95%CI上限不超过0.4则建立非劣效。
  • 主要终点采用五点评分量表评估第2-4天平均疼痛评分较基线变化。

临床怎么用

  • 阿那白滞素可作为急性痛风发作的有效治疗替代选择,尤其适用于常规治疗不适用时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy and safety of anakinra in treating acute gout flares in a randomized, double-blind, placebo-controlled, active comparator, non-inferiority (NI) trial. METHODS: Patients with a crystal-proven acute gout flare were randomized (1: 1) to treatment with anakinra or treatment as usual (free choice: either colchicine, naproxen or prednisone). The primary end point was the change in pain between baseline and the averaged pain score on days 2-4 measured on a five-point rating scale. NI of anakinra would be established if the upper bound of the 95% CI of the numeric difference in changed pain scores between treatment groups did not exceed the NI limit of 0.4 in favour of treatment as usual, in the per-protocol (PP) and intention-to-treat (ITT) populations, assessed in an analysis of covariance model. Secondary outcomes included safety assessments, improvement in pain, swelling, tenderness and treatment response after 5 days, assessed using linear mixed models and binary logistic regression models. RESULTS: Forty-three patients received anakinra and 45 treatment as usual. Anakinra was non-inferior (mean difference; 95% CI) to treatment as usual in both the PP (-0.13; -0.44, 0.18) and ITT (-0.18; -0.44, 0.08) populations. No unexpected or uncommon (serious) adverse events were observed in either treatment arm. Analyses of secondary outcomes showed that patients in both groups reported similar significant reductions in their gout symptoms. CONCLUSION: Efficacy of anakinra was shown to be non-inferior to treatment as usual for the treatment of acute gout flares, suggesting that anakinra is an effective treatment alternative for acute gout flares. TRIAL REGISTRATION: Het Nederlands Trial Register, www.trialregister.nl, NTR5234.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Janssen CA, Oude Voshaar MAH, Vonkeman HE, et al. Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology (Oxford). 2019. PMID: 30602035. doi:10.1093/rheumatology/key402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。